TSH suppressive therapy: An overview of long-term clinical consequences

Research output: Contribution to journalComment/debate

Abstract

An overview of long-term clinical consequences of TSH suppressive therapy provides evidence that serum TSH levels should be maintained at levels <0.1 mU/l in high-risk (stage III and IV) patients, whereas lower-risk patients should be allowed to have their TSH levels rise into the normal range after residual disease has been ruled out by imaging and/or stimulated thyroglobulin measurement. The proper management of patients with known residual thyroid cancer, who are also elderly or who have underlying serious comorbidities (e.g., osteoporosis, cardiovascular disease, diabetes), is uncertain and requires a high degree of clinical experience and judgment.

Original languageEnglish (US)
Pages (from-to)57-59
Number of pages3
JournalHormones
Volume9
Issue number1
DOIs
StatePublished - Jan 1 2010

Keywords

  • TSH suppression
  • Thyroid cancer
  • Thyroxin therapy

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism

Fingerprint Dive into the research topics of 'TSH suppressive therapy: An overview of long-term clinical consequences'. Together they form a unique fingerprint.

  • Cite this